

# Changing face of *Candida* colonization pattern in pediatric patients with hematological malignancy during repeated hospitalization, results of a prospective observational study (2016-2017) in Shiraz, Iran

**Sedigheh Hamzavi**

Shiraz University of Medical Sciences

**Ali Amanati** (✉ [amanati@sums.ac.ir](mailto:amanati@sums.ac.ir), [ali\\_amanati\\_1356@yahoo.com](mailto:ali_amanati_1356@yahoo.com))

Shiraz University of Medical Sciences <https://orcid.org/0000-0001-9173-2853>

**Parisa Badiie**

Shiraz University of Medical Sciences

**Mohammad Rahim Kadivar**

Shiraz University of Medical Sciences

**Hadis Jafarian**

Shiraz University of Medical Sciences

**Fatemeh Ghasemi**

Shiraz University of Medical Sciences

**Sezaneh Haghpanah**

Shiraz University of Medical Sciences

**Mansooreh Dehghani**

Shiraz University of Medical Sciences

**Abbas Norouzian Baghani**

Tehran University of Medical Sciences

---

## Research article

**Keywords:** *Candida Albicans*, Fungal Colonization, Pediatric Leukemia

**Posted Date:** April 15th, 2019

**DOI:** <https://doi.org/10.21203/rs.2.9185/v1>

**License:**   This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

**Version of Record:** A version of this preprint was published on August 30th, 2019. See the published version at <https://doi.org/10.1186/s12879-019-4372-x>.

# Abstract

**Introduction:** Surveillance of current changes in the epidemiology of Invasive Fungal Diseases (IFDs) as an important component of the antifungal stewardship programs (ASP), needs careful regular, monitoring especially in high-risk settings such as oncology centers. This study aimed at examining *Candida* colonization status and corresponding current changes in children with malignancy during repeated admissions and also investigating of possible epidemiological shifts after the implementation of ASP.

**Methods:** In this prospective observational study, all eligible patients younger than 18 years were recruited during 2016-2017 at Amir Medical Oncology Center (AMOC) in Shiraz, Iran. Totally, 136 patients were enrolled and 482 samples were collected from different sites (oral/nasal discharges, urine and stool). Weekly regular sampling was carried out during hospitalization. *Candida* colonization status and epidemiological changes were monitored during repeated admissions. Samples were cultivated on Sabouraud Dextrose agar medium and identified by Polymerase Chain Reaction -Restriction Fragment Length Polymorphism (PCR-RFLP).

**Results:** Estimated *Candida* colonization incidence was 59.9% (82/136) in our patients. *Candida* colonization was found to be higher in oral cavity and rectum than that in nasal cavity. Among those long-term follow ups and repetitive hospitalizations, a significant number of patients exhibited changes in their colonization patterns (37.7%). *Candida* colonization did not reveal any significant relationship with age, sex, oncologic diseases and degree of neutropenia. *C. albicans* (72.0%) was found as the most common *Candida* species in colonized patients, followed by *C. krusei*, *C. kefyr*, *C. glabrata* and *C. parapsilosis*.

**Conclusion:** Given the high incidence of *Candida* infections in children with cancers, close monitoring of epidemiologic change is essential for judicious management, based on local surveillance data and improvement of overall quality of care in high risk patients.

## Introduction

Prevention and management of invasive fungal diseases (IFDs) may be one of the most challenging problems in children suffering from cancer. Despite recent improvements in diagnosis and management of IFDs, we still witness high attributable morbidity and mortality in those with hematological malignancies (1, 2). Among various yeast and mold infections in immunocompromised hosts, *Candida* is the most common cause with wide spectrum clinical manifestations range from local infection to severe multi-organ involvement (3). *Candida* colonization in hematological malignancies could affect final clinical outcome, especially when colonization occurs with a strain that has reduced susceptibility to azole antifungals (4, 5). Also, with prolonged colonization during chemotherapy, the possibility of invasive candidiasis increases with the same colonized isolates (6). Although *C. albicans* literally considered as the leading cause of all *Candida* related IFDs, a shift toward non-*albicans* infections has been identified globally (7-9). Among the various types of non-*albicans* species, there is growing concern about some of them such as *C. glabrata* and *C. parapsilosis* because of varying degree of Azole antifungal resistance (3, 10). Changes in colonization may happen during repeated admissions and various risk factors may make children with hematological malignancies prone to new colonization (especially resistance ones), multi-species colonization or changed primary colonization (11). Some of

these possible risk factors may be broad-spectrum antibiotic therapy, antifungal prophylaxis, Azole antifungal misuse, various types of short/long term indwelling catheter, total parenteral nutrition, neutropenia, surgical interventions, changes in chemotherapy intensity due to refractory disease or relapse, younger age at oncologic diagnosis, repeated IFDs during course of treatment and comorbidities such as hyperglycemia (11-15). Some of these variables are known risk factor for *Candida* colonization while the role of others needs to be determined by further risk studies (16). Although attention to these risk factors and application of proper infection prevention strategies for controllable ones (prevention of Azole antifungal misuse, implementation of antimicrobial stewardship programs and prevention of unnecessary prolong catheterization) is almost always ineluctable (17), such changes in *Candida* colonization should be documented primarily in each individual during repeated admissions by frequent sampling from different possible colonization sites. This study aimed to investigate the epidemiology of *Candida* colonization and any possible changes in colonization pattern in children with malignancies as a part of regular local surveillance program in AMOC in Shiraz, Iran. Indeed, the study was conducted in the continuation of the previous research carried out in 2014 by Haddadi et al. (18) to investigate the epidemiology of *Candida* colonization and its possible changes during recurrent admission in AMOC.

## Methods

This prospective, observational study was performed during 2016 -2017 on the children hospitalized in a referral oncology teaching hospital, Shiraz, Iran. Amir Hospital is an oncology hospital with 54 beds for children and about 5000 admitted adolescents under 18 years of age per each year. It was conducted on the pediatric patients under 18 years who were suffering from hematologic malignancies or solid organ tumors. The study procedure was started after filling consent forms by patients' parents. As an observational study, demographic data were obtained using predesigned questionnaires.

To examine the rate of *Candida* colonization, oral, urine, nasal, and stool samples were collected upon admission in the wards. Only urine and stool samples were collected from those with severe thrombocytopenia or any type of bleeding tendency and oral and nasal samples were withheld in such cases. To observe the changes in colonization pattern during hospitalization, weekly sampling was performed during total course of admission. The *Candida* colonization index (CI), was calculated as the ratio of the number of non-blood body sites colonized by *Candida* spp. to the total number of body sites cultured. Samples were cultivated on Sabouraud Dextrose Agar Medium (Merck, Germany). The cultivated Sabouraud Dextrose Agar plates were incubated in ambient temperature and then, the species were identified at mycology division of *Professor Alborzi Clinical Microbiology Research Center* (PACMRC). To identify the species of filamentous fungi, direct microscopic examination from culture medium (lactophenol cotton blue) was done. *Candida* spp. were identified by formation of germ tube and PCR-RFLP (Polymerase Chain Reaction -Restriction Fragment Length Polymorphism) using forward ITS11 (5'-TTCCGTAGGTGAACCTGCGG-3') and reverse ITS4 (5'-TCCTCCGCTTATTGATATGC-3') primers. The products were digested using *MspI* (#ER0541) restriction enzyme (19). The normal distribution was confirmed by Kolmogorov-Smirnov test and the obtained data were analyzed by independent sample T-test and Chi-square test by SPSS version 21.0 (IBM Corp. IBM SPSS Statistics for Windows, Armonk, NY).

The significance level (P-value) of all tests was below 0.05 and  $\alpha = 0.05$ . Comparison of the proportions between the present study and our recent study in 2011-2012, was done using MedCalc Software bvba, Version 18.9.1.

## Results

### Demographics

After exclusion, 136 pediatric patients younger than 18 years were recruited in the study and totally, 482 samples were collected from different sites (oral/nasal discharges, urine and stool). Among them 82 (59.9%) were male. The average age was calculated 7.1 years-old ( $6 \pm 4.69$  SD; 4 and 18, minimum and maximum, respectively). Detailed data about sex and patient's age category is shown in Table 1. As for the primary underlying disease, *Acute Lymphoblastic Leukemia* (ALL) was the most common oncologic diagnosis (41, 30.1%). Close to 85% (115/136) of the patients had history of recurrent admission (Table 1). The colonization rate was greater in patients with history of recurrent admission (61.7% versus 38.3%). Totally, 39% of patients had long term follow up. Of special note, among children with long term follow up, 71.7% were colonized. In this subgroup of patients, repeated admission was found to be correlated with greater chance of *Candida* colonization (P-value = 0.014). Common oncological diagnosis and also their colonization status have been shown in Figure 1.

### Samples' characteristics

482 samples were collected from different sites and finally 140 positive samples were analyzed (excluding negative cultures). About 80% of patients underwent at least two-time sampling (based on weekly sampling protocol) and more than 20% underwent 3 times or more. Among the collected samples, 195 (40%) were from oral cavity, 220 (46%) from nasal discharges, 44 (9%) from urine, and 24 (5%) from stool. There was no significant difference between colonized and non-colonized patients with regard to age category and sex (P-value = 0.088 and 0.593, respectively).

### Colonization status

#### A. Patient's colonization status

*Candida* colonization was found in 59.9% (82/136) of the patients. Most children exhibited oral colonization (67.1%). Oral/Rectal colonization (11%) was the second most common type of colonization among the studied children (Table 2). 72% of the children were colonized with *C. albicans*, followed by *C. krusei* (9.8%), *C. kefyr* (7.3%), *C. glabrata* (2.4%) and *C. parapsilosis* (2.4%). Among the studied patients, one had double colonization with *C. kefyr* and *C. parapsilosis* and another one with *C. albicans* and *C. tropicalis*. Data regarding distribution of different colonization sites in colonized children are presented in

Table 2. Calculated mean *Candida* CI was  $3.11 \pm 0.121$  [1:4 (78%), 2:4 (19.5%) and 3:4 (2.4%)]. Colonization site preferences were analyzed by Chi-Square Tests for age, sex, degree of neutropenia, primary oncologic diagnosis and recurrent versus new admission (Table 3), revealing no significant differences ( $p=0.531$ ,  $p=0.304$ ,  $0.125$ ,  $0.551$  and  $0.797$ , respectively). Also, *Candida* CI was investigated for these variables that revealed no significant differences, either ( $p=0.650$ ,  $p=0.246$ ,  $0.259$ ,  $0.701$  and  $0.307$ , respectively).

## B. Sample's characteristics

From 140 positive samples (excluding black yeasts), species type was determined in 130 samples (10 samples were not recognized). Oral cavity was the most common site of colonization (Figure 2), followed by nasal cavity and rectum, 98 (75.4%), 12 (9.2%) and 20 (15.4%), respectively (calculated from all positive samples). Of special note, in this study we did not find any urinary *Candida* colonization among the studied children. Regarding sex differences, we did not observe any correlation between colonization status and sex ( $P$ -value = 0.593). In terms of age distribution, most of colonized children were over 5 years (53, 63.1%) and the rest 1-5 years (29, 59.2%). Although colonization rate was directly correlated with age category (greater in patients >5 years), the difference was not significant ( $P$ -value = 0.088, LR: 0.05). *Candida* colonization status was investigated based on different underlying oncologic diagnoses. ALL and AML were the most common diagnoses in both colonized and non-colonized children without any significant difference ( $P$ -value = 0.432). No statistically significant relationship was found between *Candida* colonization and the severity of neutropenia during admission ( $P$ -value = 0.166).

## C. *Candida* species characteristics

Among the different types of recognized *Candida* species (140 spp.), *C. albicans* was the most common (72%), followed by *C. krusei* (9.8%), *C. kefyr* (7.3%), *C. glabrata* (2.4%) and *C. parapsilosis* (2.4%); data are shown in figure 3. Of the studied patients, one had double colonization with *C. kefyr* and *C. parapsilosis* and another with *C. albicans* and *C. tropicalis*. A small proportion of the species could not be distinguished phenotypically on culture media and was categorized as "Not defined" (10 samples). Detailed data regarding different *Candida* species in oral and nasal discharges, and stool samples are summarized in Table 4.

## D. Monitoring of colonization pattern during patient's follow up

On average, 53 cases were followed for at least 4 weeks (26.87 days  $\pm$ SD: 39.6). Follow up duration also was categorized in four-time frame as <30 days, 30-60 days, 60-90 days and >90 days. More than 64% of colonized children were followed for more than 4 weeks (Table 5).

During the study period, 6.1% of monitored cases had changes in their colonization patterns, indicating non-colonization to colonization and vice versa and also change in candida species (Table 6). During repeated sampling, in 2.2% of colonized cases, colonization was not continued (that means negative culture on two occasions at least two weeks apart).

The association between recurrent admissions and any type of colonization status change were assessed by Chi-Square Tests which revealed a significant correlation ( $p=0.035$ ).

## Discussion

Without systematic use of antifungal prophylaxis, invasive *Candida* infections account for the most prevalent type of IFDs in onco-hematological centers (14, 18, 20) and usually is considered as a consequence of primary colonization (17). In this study, nearly 60% of all investigated children were colonized with different *Candida* species. Compared to our recent study in 2011-2012 (18), we found important findings which needs special consideration.

First, compared to the previous study, we found a substantial increase in colonization rate (47% versus 59.9%) [Difference 13.4%, 95% CI: 2.39% to 23.91%,  $P = 0.0173$ ]. In addition to possibly true increases in the incidence of *Candida* colonization, this increase also could be partially due to regular sampling program which was conducted by the main investigator during study period.

Second, we found that *Candida non-Albicans* colonization rate decreased significantly from 38% to 18.5% ( $P = 0.0003$ ). Although antifungal prophylaxis in onco-hematological patients receiving intensive chemotherapy is encouraged based on logical argument for reducing mucosal colonization and consequently systemic invasive disease, prolonged azole exposure during antifungal prophylaxis also is considered an important risk factor for shifting in epidemiology of candidiasis (20, 21). Due to the very low incidence of proven and probable invasive *Candida* infections in AMOC, currently (after October 2015) Azole prophylaxis is not routinely used in pediatric patients with hematological malignancies as a part of antifungal stewardship program (ASP). Along with other reports this strategy may explain such a decrease in *Candida non-Albicans* colonization rate despite a total increase in the incidence of *Candida* colonization and emphasis on the role of ASP in controlling undesired changing in the epidemiology of candidiasis (21, 22).

Third, similar to our previous report, *C. Krusei* was the most prevalent type of *non-Albicans* species in colonized children. As known, *C. Krusei* usually is considered as an important Azole-resistant *non-Albicans* colonizer with high MIC to fluconazole and voriconazole (10).

Fourth, we found some increase in the prevalence of *C. Parapsilosis* and conversely significant decrease in *C. Famata* prevalence in this study. *C. Parapsilosis* was the second most common *non-Albicans* species in colonized children, just after *C. Krusei*, whereas in our previous study *C. Glabrata*, *C. Tropicalis* and *C. Famata* were more prevalent than *C. Parapsilosis*. This is of utmost importance because increased

resistance to Azoles frequently was seen with *C. Parapsilosis* (23). Corresponding data regarding common *non-Albicans* species were shown in Table 7.

Comparable to the previous study in AMOC, ALL was found as the most common oncologic diagnosis in children with hematological malignancies. While acute leukemia was the most common diagnosis in different similar studies, the leukemia type may vary, based on different geographic regions (6, 16). In contrast to the study by Albert et al (24), we did not find any relationship between colonization status or its change with neutropenia. Treatment of newly diagnosed standard risk ALL usually leads to the first successful remission. Excluding a small number of patients with acceptable response to induction chemotherapy, others usually undergo consequent phases of treatment leading to prolonged maintenance treatment phase which is based on the administration of less intensive regimen on an outpatient basis (25). There are several causes that lead to repeated admissions for children with hematological malignancies and such children have greater hospitalization rate, (more than 2-folds), compared to the general population (26). The possible role of recurrent hospitalization on *Candida* colonization pattern in children with hematological malignancies has not been determined exactly and in this study, we decided to address this issue. More than two-thirds of our studied cases were on maintenance chemotherapy with recurrent admissions. Although *Candida* colonization rate was significantly greater (more than 6:1) in patients with history of recurrent admission, difference was not statistically significant ( $p=0.420$ ). However, we found that in the subgroup of children with long term follow up, repeated admission was significantly correlated with a higher *Candida* colonization rate. Similar to other reports (27), oral cavity was the most common *Candida* colonization site both in this study and our previous report in 2014 (18), but we found some considerable changes in the present study. First, compared to the previous study, the rate of oral colonization significantly increased (75.4% versus 38.4%). Secondly, we did not find any urinary colonization in this study (Table 6). This may be due to successful adherence to AFS (avoidance of unnecessary catheterization, timely removal of unnecessary catheters and last but not least implementation of antimicrobial stewardship program in our center).

Finally, reports on epidemiologic changes in *Candida* colonization during repeated admissions are somewhat lacking in the literature, especially in children with malignancy (28). Our study confirmed that repeated hospitalization in children with malignancy (especially those with ALL) has an important role in changing the face of *Candida* colonization. Consistent with the study by Kaben et al (29), we observed some changes to *non-Albicans* species during hospitalization (5.1%, Table 5).

## Limitations

This study has some limitations. We encountered inevitable limitations in regular and timely sampling from all pre-defined sites due to uncontrolled patients' clinical situations. Among them we could mention increased bleeding tendency, thrombocytopenia, delay in taking urine and stool samples in young infants.

## Conclusions

Changing face of *Candida* colonization pattern among high-risk colonized children with different types of malignancies may warrant judicious use of Azoles agents and an urgent need for the implementation of ASP to reduce colonization of resistant *Candida* spp.

## Abbreviations

AMOC: Amir Medical Oncology Center

PACMRC: Professor Alborzi clinical microbiology research center

IFDs: Invasive Fungal Diseases

CI: Colonization Index

ASP: Antifungal Stewardship Program

## Declarations

### Ethics, consent and permissions

The study was approved by medical ethics committee of *Professor Alborzi clinical microbiology research center*.

### Informed consent

All individuals (or their parents) in the study population were informed about the current study, with a written consent form taken from each before her or his enrolment in the present study.

### Availability of data and material

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

### Competing interests

The authors do not have any financial or other relationships which could be regarded as a conflict of interest.

## Funding

Not applicable

## Author contributions:

Study concept and design: Amanati A and Kadivar MR; Acquisition of data: Amanati A, Hamzavi S, Dehghani M, Norouzian Baghani A; Mycological analysis: Badiee P, Jafarian H, Ghasemi F; Analysis and interpretation of data: Amanati A, Hamzavi S, Haghpanah S; Drafting of the manuscript: Amanati A., Critical revision of the manuscript for important intellectual content: Amanati A, Badiee P; Study supervision: Amanati A. Badiee P.

## Acknowledgment

Our thanks go to Keliddar Mohammadi Mohammad Ebrahim (Senior expert of Hospital Information System [HIS] at Shiraz University of Medical Sciences), Salma Mehrangiz (infection control unit staff), Khaje Somaye (microbiology department staff), all members of infection control team in AMOC, for their technical support and assistance with the implementation of ASP in AMOC. Our gratitude also to Dr. Hassan Khajehei, for careful linguistic editing of the manuscript.

## References

1. Natesan SK. Emerging Fungal Infections in Cancer Patients-A Brief Overview. *Medical Mycology: Open Access*. 2016;**2**(3).
2. Colombo A, de Almeida Júnior J, Slavin MA, Chen SC, Sorrell TC. Candida and invasive mould diseases in non-neutropenic critically ill patients and patients with haematological cancer. *The Lancet Infectious Diseases*. 2017;**17**(11):e344-e56.
3. Bassetti M, Peghin M, Timsit J-F. The current treatment landscape: candidiasis. *Journal of Antimicrobial Chemotherapy*. 2016;**71**(suppl\_2):ii13-ii22.
4. Safdar A, Armstrong D. Prospective evaluation of Candida species colonization in hospitalized cancer patients: impact on short-term survival in recipients of marrow transplantation and patients with hematological malignancies. *Bone marrow transplantation*. 2002;**30**(12):931.
5. Hovi L, Saarinen-Pihkala U, Vettenranta K, Saxen H. Invasive fungal infections in pediatric bone marrow transplant recipients: single center experience of 10 years. *Bone marrow transplantation*. 2000;**26**(9):999.
6. Dalle F, Lafon I, L'Ollivier C, Ferrant E, Sicard P, Labruère C, *et al*. A prospective analysis of the genotypic diversity and dynamics of the Candida albicans colonizing flora in neutropenic patients with de novo acute leukemia. *Haematologica*. 2008;**93**(4):581-7.

7. Jensen RH. Resistance in human pathogenic yeasts and filamentous fungi: prevalence, underlying molecular mechanisms and link to the use of antifungals in humans and the environment. *Dan Med J.* 2016;**63**:1-34.
8. Guinea J. Global trends in the distribution of *Candida* species causing candidemia. *Clinical Microbiology and Infection.* 2014;**20**:5-10.
9. Cleveland AA, Harrison LH, Farley MM, Hollick R, Stein B, Chiller TM, *et al.* Declining incidence of candidemia and the shifting epidemiology of *Candida* resistance in two US metropolitan areas, 2008–2013: results from population-based surveillance. *PLoS One.* 2015;**10**(3):e0120452.
10. Alcazar-Fuoli L, Mellado E. Current status of antifungal resistance and its impact on clinical practice. *British journal of haematology.* 2014;**166**(4):471-84.
11. Schulte DM, Sethi A, Gangnon R, Duster M, Maki DG, Safdar N. Risk factors for *Candida* colonization and Co-colonization with multi-drug resistant organisms at admission. *Antimicrobial resistance and infection control.* 2015;**4**(1):46.
12. Marodi L, Johnston Jr RB. Invasive *Candida* species disease in infants and children: occurrence, risk factors, management, and innate host defense mechanisms. *Current opinion in pediatrics.* 2007;**19**(6):693-7.
13. Lai Y, Bao L, Lu X, Lu J, Yu J, Li R, *et al.* *Candida* colonization and invasive fungal infection in hospitalized patients with hematological malignancies. *Zhonghua yi xue za zhi.* 2009;**89**(4):239-42.
14. Li D, Xia R, Zhang Q, Bai C, Li Z, Zhang P. Evaluation of candidemia in epidemiology and risk factors among cancer patients in a cancer center of China: an 8-year case-control study. *BMC infectious diseases.* [journal article]. 2017;**17**(1):536.
15. Cortes J, Corrales I. Invasive Candidiasis: Epidemiology and Risk Factors. *Fungal Infection: IntechOpen*; 2018.
16. Gammelsrud K, Sandven P, Høiby E, Sandvik L, Brandtzaeg P, Gaustad P. Colonization by *Candida* in children with cancer, children with cystic fibrosis, and healthy controls. *Clinical Microbiology and Infection.* 2011;**17**(12):1875-81.
17. Clarkson JE, Worthington HV, Eden TO. Interventions for preventing oral candidiasis for patients with cancer receiving treatment. *The Cochrane Library.* 2007.
18. Haddadi P, Zareifar S, Badiie P, Alborzi A, Mokhtari M, Zomorodian K, *et al.* Yeast colonization and drug susceptibility pattern in the pediatric patients with neutropenia. *Jundishapur journal of microbiology.* 2014;**7**(9).
19. Mirhendi H, Makimura K, Khoramizadeh M, Yamaguchi H. A one-enzyme PCR-RFLP assay for identification of six medically important *Candida* species. *Nippon Ishinkin Gakkai Zasshi.* 2006;**47**(3):225-9.
20. Lamoth F, Lockhart SR, Berkow EL, Calandra T. Changes in the epidemiological landscape of invasive candidiasis. *Journal of Antimicrobial Chemotherapy.* 2018;**73**(suppl\_1):i4-i13.
21. Mellingshoff SC, Panse J, Alakel N, Behre G, Buchheidt D, Christopeit M, *et al.* Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the

- recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO). *Annals of hematology*. 2018;**97**(2):197-207.
22. Aguado JM, Silva JT, Bouza E. Conclusion and future perspectives on antifungal stewardship. *Journal of Antimicrobial Chemotherapy*. 2016;**71**(suppl\_2):ii43-ii4.
23. Hii M, Chang H-L, Lin L-C, Lee Y-L, Liu Y-M, Liu C-E, *et al*. Changing epidemiology of candidemia in a medical center in middle Taiwan. *Journal of Microbiology, Immunology and Infection*. 2015;**48**(3):306-15.
24. Alberth M, Majoros L, Kovalecz G, Borbás E, Szegedi I, Márton IJ, *et al*. Significance of oral Candida infections in children with cancer. *Pathology & Oncology Research*. 2006;**12**(4):237.
25. Cooper SL, Brown PA. Treatment of pediatric acute lymphoblastic leukemia. *Pediatric Clinics*. 2015;**62**(1):61-73.
26. Sieswerda E, Font-Gonzalez A, Reitsma JB, Dijkgraaf MG, Heinen RC, Jaspers MW, *et al*. High hospitalization rates in survivors of childhood cancer: a longitudinal follow-up study using medical record linkage. *PLoS One*. 2016;**11**(7):e0159518.
27. Kumar CPG, Sundararajan T, Menon T, Venkatadesikal M. Candidosis in children with onco-hematological diseases in Chennai, south India. *Japanese journal of infectious diseases*. 2005;**58**(4):218.
28. Fanello S, Bouchara J, Sauteron M, Delbos V, Parot E, Marot-Leblond A, *et al*. Predictive value of oral colonization by Candida yeasts for the onset of a nosocomial infection in elderly hospitalized patients. *Journal of medical Microbiology*. 2006;**55**(2):223-8.
29. Kaben U, Blaschke-Hellmessen R, Hellwig S. Persistence and variability of yeasts isolated from hospitalized patients: a comparison of results from Rostock and Dresden. *Mycoses*. 1997;**40**:76-80.

## Tables

**Table 1. Demographic data in colonized and non- colonized children with malignancy**

		Colonization status				P. value <sup>a</sup>
		Yes		No		
		Count	%	Count	%	
Gender	Female	35	63.6%	20	36.4%	.512
	Male	47	58.0%	34	42.0%	
Age group	≤12 months	0	0.0%	3	100.0%	.088
	1-5 years	29	59.2%	20	40.8%	
	>5 years	53	63.1%	31	36.9%	
Neutropenia (ANC <1500)	Yes	46	65.7%	24	34.3%	.160
	No	35	53.8%	30	46.2%	
History of admission	First admission	11	52.4%	10	47.6%	.420
	Recurrent admission	71	61.7%	44	38.3%	

a. P-value by Fisher's Exact Test

**Table 2. Distribution of different colonization sites in 82 colonized children with malignancy <sup>a</sup>**

	Frequency	Valid Percent	Cumulative Percent
Oral	55	67.1	67.1
Nasal	3	3.7	70.7
Fecal	6	7.3	78.0
Oral/Nasal	6	7.3	85.4
Oral/Rectal	9	11.0	96.3
Nasal/ Rectal	1	1.2	97.6
Oral/Nasal/ Rectal	2	2.4	100.0
Total	82	100.0	

a. Urinary colonization was not found

**Table 3**

Due to technical limitations, Table 3 has been placed in the Supplementary Files section.

**Table 4. The prevalence of colonization with different *Candida* species in oral and nasal discharges, and stool and urine samples**

Total samples (number)	Candida species	Number of positive samples	Prevalence (% of total oral samples)
Oral (195)	<i>C. Albicans</i>	83	77.6
	<i>C. Krusei</i>	4	3.7
	<i>C. Parapsilosis</i>	4	3.7
	<i>C. Glabrata</i>	3	2.8
	<i>C. Kefyr</i>	2	1.8
	<i>C. Tropicalis</i>	2	1.8
	Not defined	9	8.4
Nasal (220)	<i>C. Albicans</i>	10	76.9
	<i>C. kefir</i>	1	7.6
	<i>C. Famata</i>	1	7.6
	Not defined	1	7.6
Stool (24)	<i>C. Albicans</i>	13	65
	<i>C. Krusei</i>	3	15
	<i>C. Kefyr</i>	1	5
	<i>C. Parapsilosis</i>	1	5
	<i>C. Glabrata</i>	1	5
	<i>C. Tropicalis</i>	1	5
Urine (44) *	-	-	-

\* No colonization was found in urine specimens

**Table 5. Follow-up time frames in colonized children with malignancy**

	Count	%	Cumulative Percent
Follow-up time frames >90 days	14	26.4	26.4
60-90 days	11	20.7	47.1
30-60 days	9	16.9	64.2
<30 days	19	35.8	100
Total	53	100	

**Table 6. Significant changes in colonization status during follow-up**

	Frequency	Percent <sup>a</sup>	Valid Percent <sup>b</sup>	Cumulative Percent
"No colonization" to "colonization"	10	7.4	50.0	50.0
Change to "colonization with other candida species"	7	5.1	35.0	85.0
"Decolonization" <sup>c</sup>	3	2.2	15.0	100.0
Total	20	14.7	100.0	

a. From total colonized cases

b. Calculated from those in whom colonization change were detected

c. Negative culture on two occasions at least two weeks apart

**Table 7. Colonization characteristics in both studies conducted in AMOC, in children who were colonized with different Candida species**

Candida species <sup>a</sup>	2017-2018		2011-2012 (18)		p-value <sup>c</sup>
	N <sup>b</sup>	%	N <sup>b</sup>	%	
<i>C. Albicans</i>	106	81.6	117	62	<b>0.0003*</b>
<i>C. Krusei</i>	7	5.4	18	9.6	0.2477
<i>C. Parapsilosis</i>	5	3.9	8	4.3	0.9126
<i>C. Glabrata</i>	4	3.1	14	7.5	0.1559
<i>C. Kefyr</i>	4	3.1	4	2.2	0.8893
<i>C. Tropicalis</i>	3	2.4	11	5.9	0.2262
<i>C. Famata</i>	1	0.8	11	5.9	<b>0.0416*</b>
Albicans versus non-Albicans Candida species					
Albicans	106	81.6	117	62	<b>0.0003*</b>
Non-Albicans	24	18.5	72	38	<b>0.0003*</b>
Colonization site					
Oral	98	75.4	88	38.4	<b>&lt;0.0001*</b>
Nasal	12	9.2	24	10.4	0.8560
Rectal	20	15.4	77	33.6	<b>0.0003*</b>
Urine	0	0	40	17.4	<b>&lt;0.0001*</b>

a. Very rare species including *C. Guilliermondii*, *C. Rugosa*, *C. Lusitaniae*, *C. Lambica*, and *Rhodotorula spp.* were excluded from 2011-2012 study

b. Number of positive samples

c. Chi-square test

\* Statistically significant

## Figures





Figure 1

Candida colonization status in children with different malignancies. Data are shown based on the most common oncologic diagnosis (data presented in number). Difference was not significant (see text for more information).



**Figure 2**

Distribution of different *Candida* spp. in oral cavity, nasal cavity and rectum among colonized patients.



**Figure 3**

Different *Candida* spp. which were recognized in colonized patients (among 131 identified samples including black yeast).

## Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [supplement1.png](#)